본문 바로가기
KERD
논문KCI 등재

Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines

김형영|송여진|Tae-Han Lee|Yoon-Kyoung Sung|Soo-Kyung Cho
대한골대사학회 (The Korean Society of Bone Metabolism)|2020.11|대한골대사학회지 (Journal of Bone Metabolism)|제27권 제4호|pp. 247-259

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류정형외과학

초록

Background: In this study, we aimed to evaluate and compare the treatment indication for patients with glucocorticoid-induced osteoporosis (GIOP) in various clinical practice guidelines. Methods: We searched for potentially relevant studies conducted from January 2000 to March 2020 using online databases, including PubMed, Ovid-EMBASE, Guidelines International Network, National Institute for Health and Clinical Excellence, KoreaMed, KMbase, and KoMGI. We reviewed and analyzed the guidelines that included recommendations on GIOP and fulfilled the inclusion criteria. Results: A total of 94 articles were selected based on review of the title and abstract; 14 guidelines were assessed upon reviewing the full text. The bone mineral density score for therapeutic intervention of GIOP in postmenopausal women was presented in 7 guidelines, among which 3 guidelines set a T-score of −2.5 or lower and the other 4 guidelines proposed a less stringent cut-off point of −1.5 or lower. Among the 10 guidelines published since 2012 after the emergence of the fracture risk assessment tool (FRAX), 6 guidelines included FRAX in their criteria for defining intervention thresholds. However, they were further divided into fixed-probability (n=3) and age-dependent (n=3) thresholds based on the country. Conclusions: Recently developed guidelines use FRAX as the criterion for establishing the treatment of patients with GIOP. However, these intervention thresholds need to be adapted for each country.

Abstract

Background: In this study, we aimed to evaluate and compare the treatment indication for patients with glucocorticoid-induced osteoporosis (GIOP) in various clinical practice guidelines. Methods: We searched for potentially relevant studies conducted from January 2000 to March 2020 using online databases, including PubMed, Ovid-EMBASE, Guidelines International Network, National Institute for Health and Clinical Excellence, KoreaMed, KMbase, and KoMGI. We reviewed and analyzed the guidelines that included recommendations on GIOP and fulfilled the inclusion criteria. Results: A total of 94 articles were selected based on review of the title and abstract; 14 guidelines were assessed upon reviewing the full text. The bone mineral density score for therapeutic intervention of GIOP in postmenopausal women was presented in 7 guidelines, among which 3 guidelines set a T-score of −2.5 or lower and the other 4 guidelines proposed a less stringent cut-off point of −1.5 or lower. Among the 10 guidelines published since 2012 after the emergence of the fracture risk assessment tool (FRAX), 6 guidelines included FRAX in their criteria for defining intervention thresholds. However, they were further divided into fixed-probability (n=3) and age-dependent (n=3) thresholds based on the country. Conclusions: Recently developed guidelines use FRAX as the criterion for establishing the treatment of patients with GIOP. However, these intervention thresholds need to be adapted for each country.

참고문헌 (50)

  1. Fardet L, "Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years", Rheumatology(Oxford), 50, pp.1982~1990 (2011)[DOI]
  2. Robert A. Overman, "Prevalence of oral glucocorticoid usage in the United States: A general population perspective", Arthritis Care & Research, 65(2), pp.294~298 (2013), Wiley[DOI]
  3. Joo-Hyun Lee, "The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritis", BMC Musculoskeletal Disorders, 17(1) (2016), Springer Science and Business Media LLC[DOI]
  4. T. P. Van Staa, "Use of Oral Corticosteroids and Risk of Fractures", Journal of Bone and Mineral Research, 15(6), pp.993~1000 (2000), Wiley[DOI]
  5. van Staa TP, "Oral corticosteroids and fracture risk: relationship to daily and cumulative doses", Rheumatology(Oxford), 39, pp.1383~1389 (2000)[DOI]
  6. L. Dalle Carbonare, "Comparison of Trabecular Bone Microarchitecture and Remodeling in Glucocorticoid-Induced and Postmenopausal Osteoporosis", Journal of Bone and Mineral Research, 16(1), pp.97~103 (2001), Wiley[DOI]
  7. T. P. van Staa, "The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis", Osteoporosis International, 13(10), pp.777~787 (2002), Springer Science and Business Media LLC[DOI]
  8. Michael Steinbuch, "Oral glucocorticoid use is associated with an increased risk of fracture", Osteoporosis International, 15(4), pp.323~328 (2004), Springer Science and Business Media LLC[DOI]
  9. Juliet Compston, "Glucocorticoid-induced osteoporosis: an update", Endocrine, 61(1), pp.7~16 (2018), Springer Science and Business Media LLC[DOI]
  10. J. Compston, "UK clinical guideline for the prevention and treatment of osteoporosis", Archives of Osteoporosis, 12(1) (2017), Springer Science and Business Media LLC[DOI]
  11. Lenore Buckley, "2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis", Arthritis & Rheumatology, 69(8), pp.1521~1537 (2017), Wiley[DOI]
  12. 박소영, "Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis", 대한골대사학회지, 25(4), pp.195~211 (2018), 대한골대사학회
  13. Alessandro Liberati, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration", Journal of Clinical Epidemiology, 62(10), pp.e1~e34 (2009), Elsevier BV[DOI]
  14. M. C. Brouwers, "AGREE II: advancing guideline development, reporting and evaluation in health care", Canadian Medical Association Journal, 182(18), pp.E839~E842 (2010), Joule Inc.[DOI]
  15. Bone and Tooth Society of Great Britain, "Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment", Royal College of Physicians, ~ (2002)
  16. Jean-Pierre Devogelaer, "Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club", Osteoporosis International, 17(1), pp.8~19 (2006), Springer Science and Business Media LLC[DOI]
  17. Dachverband Osteologie e. V., "DVO Guideline 2009 for Prevention, Diagnosis and Therapy of Osteoporosis in Adults", Osteologie, 20(01), pp.55~74 (2017), Georg Thieme Verlag KG[DOI]
  18. A. Papaioannou, "2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary", Canadian Medical Association Journal, 182(17), pp.1864~1873 (2010), Joule Inc.[DOI]
  19. Pereira RM, "Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis", Rev Bras Reumatol, 52, pp.580~593 (2012)
  20. S. Lekamwasam, "A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis", Osteoporosis International, 23(9), pp.2257~2276 (2012), Springer Science and Business Media LLC[DOI]
  21. Yasuo Suzuki, "Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update", Journal of Bone and Mineral Metabolism, 32(4), pp.337~350 (2014), Springer Science and Business Media LLC[DOI]
  22. Karine Briot, "2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis", Joint Bone Spine, 81(6), pp.493~501 (2014), Elsevier BV[DOI]
  23. J. González-Macías, "Guías de práctica clínica en la osteoporosis posmenopáusica, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral (3.ª versión actualizada 2014)", Revista Clínica Española, 215(9), pp.515~526 (2015), Elsevier BV[DOI]
  24. M. Rossini, "Guidelines for the diagnosis, prevention and management of osteoporosis", Reumatismo, 68(1), pp.1~39 (2016), PAGEPress Publications[DOI]
  25. Antonio Naranjo Hernández, "Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis", Reumatología Clínica, 15(4), pp.188~210 (2019), Elsevier BV[DOI]
  26. Frank De Vries, "Fracture risk with intermittent high-dose oral glucocorticoid therapy", Arthritis & Rheumatism, 56(1), pp.208~214 (2007), Wiley[DOI]
  27. T. P. Van Staa, "Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy", Arthritis & Rheumatism, 48(11), pp.3224~3229 (2003), Wiley[DOI]
  28. John A Kanis, "A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk", Journal of Bone and Mineral Research, 19(6), pp.893~899 (2004), Wiley[DOI]
  29. E. S. Leib, "Bone status in glucocorticoid-treated men and women", Osteoporosis International, 27(1), pp.39~48 (2016), Springer Science and Business Media LLC[DOI]
  30. Kenneth G. Saag, "Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide", Arthritis & Rheumatology, 68(9), pp.2122~2128 (2016), Wiley[DOI]
  31. E. Canalis, "Glucocorticoid-induced osteoporosis: pathophysiology and therapy", Osteoporosis International, 18(10), pp.1319~1328 (2007), Springer Science and Business Media LLC[DOI]
  32. American College of Rheumatology Ad Hoc Committee on Glucocorticoid‐Induced Osteoporosis, "Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update", Arthritis & Rheumatism, 44(7), pp.1496~1503 (2001), Wiley[DOI]
  33. K. Briot, "Glucocorticoid-induced osteoporosis", RMD Open, 1(1), pp.e000014~e000014 (2015), BMJ[DOI]
  34. John A Kanis, "Diagnosis of osteoporosis and assessment of fracture risk", The Lancet, 359(9321), pp.1929~1936 (2002), Elsevier BV[DOI]
  35. John A. Kanis, "Overview of Fracture Prediction Tools", Journal of Clinical Densitometry, 20(3), pp.444~450 (2017), Elsevier BV[DOI]
  36. Andréa Marques, "The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis", Annals of the Rheumatic Diseases, 74(11), pp.1958~1967 (2015), BMJ[DOI]
  37. J. A. Kanis, "FRAX™ and the assessment of fracture probability in men and women from the UK", Osteoporosis International, 19(4), pp.385~397 (2008), Springer Science and Business Media LLC[DOI]
  38. F. Cosman, "Clinician’s Guide to Prevention and Treatment of Osteoporosis", Osteoporosis International, 25(10), pp.2359~2381 (2014), Springer Science and Business Media LLC[DOI]
  39. Jennifer M. Grossman, "American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis", Arthritis Care & Research, 62(11), pp.1515~1526 (2010), Wiley[DOI]
  40. Edward S. Leib, "Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture", Journal of Clinical Densitometry, 14(3), pp.212~219 (2011), Elsevier BV[DOI]
  41. J. A. Kanis, "Guidance for the adjustment of FRAX according to the dose of glucocorticoids", Osteoporosis International, 22(3), pp.809~816 (2011), Springer Science and Business Media LLC[DOI]
  42. Noa Dagan, "External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study", BMJ, 356, pp.i6755~ (2017), BMJ[DOI]
  43. C. Beaudoin, "Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression", Osteoporosis International, 30(4), pp.721~740 (2019), Springer Science and Business Media LLC[DOI]
  44. Jessica C. Wilson, "Incidence and Risk of Glucocorticoid‐Associated Adverse Effects in Patients With Rheumatoid Arthritis", Arthritis Care & Research, 71(4), pp.498~511 (2019), Wiley[DOI]
  45. Juan Meng, "Evaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis", Medicine, 96(18), pp.e6677~ (2017), Ovid Technologies (Wolters Kluwer Health)[DOI]
  46. Ratanapha Phuan-udom, "The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis", Clinical Rheumatology, 37(10), pp.2603~2610 (2018), Springer Science and Business Media LLC[DOI]
  47. 이주현, "Are glucocorticoid-induced osteoporosis recommendations suffi cient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?", The Korean Journal of Internal Medicine, 29(4), pp.509~515 (2014), 대한내과학회[DOI]
  48. John A. Kanis, "A systematic review of intervention thresholds based on FRAX", Archives of Osteoporosis, 11(1) (2016), Springer Science and Business Media LLC[DOI]
  49. J. A. Kanis, "Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK", Osteoporosis International, 19(10), pp.1395~1408 (2008), Springer Science and Business Media LLC[DOI]
  50. Chang-Hee Suh, "Korean Guideline of Glucocorticoid-induced Osteoporosis; Time to Prevent Fracture!", 대한류마티스학회지, 26(2), pp.87~89 (2019), 대한류마티스학회[DOI]

관련 논문AI추천

Korean Guideline for the Prevention and Treatment of Glucocorticoid-induced Osteoporosis김담, 김경민, 김상원, 김하영, 김현식, 박동아, 박소영, 성윤경, 이신석, 전찬홍, 주지현대한골대사학회 · 대한골대사학회지2018 · 제25권 제4호Agreement between the Turkey Guidelines and the Fracture Risk Assessment Tool®-based Intervention ThresholdAhmet Imerci, Kursad Tosun, Nevres Hurriyet Aydogan대한골대사학회 · 대한골대사학회지2018 · 제25권 제2호Routine Application of the Korean FRAX Model in Women: a Single-center Study김태희, 박준식, 이수진, 이우석, 이해혁, 정수호대한골대사학회 · 대한골대사학회지2012 · 제19권 제1호Individualized Fracture Prevention for Postmenopausal Women with OsteopeniaJaeyen Song, Jisu Mun, Junghyun Park, Jungyoon Park, Meeran Kim, Younjee Chung대한폐경학회 · 대한폐경학회지2025 · 제31권 제3호Glucocorticoid-induced Osteoporosis: From Pathogenesis to Treatment정윤석대한골다공증학회 · OSTEOPOROSIS2009 · 제7권 제3호Physicians’ Attitudes on Management of Osteopenia in South Korea구경회, 이영균, Hong Seok Kim, Joo Hyung Ha, Samuel Jaeyoon Won대한골대사학회 · 대한골대사학회지2020 · 제27권 제3호

이 간행물의 다른 논문 (7건)

The Role of Toll-Like Receptors in OsteoclastogenesisMijung Yimpp. 227-235Does Hip Bone Density Differ between Paretic and Non-Paretic Sides in Hemiplegic Stroke Patients? and Its Relationship with Physical ImpairmentHyanglim Lee, 김태우, 유승돈, 이후영, Jung Hyun Parkpp. 237-246The 2nd Metacarpal Cortical Index as a Simple Screening Tool for OsteopeniaRuss Jeffers, David Dickson, Bhavika Patel, Adeel Aqil, Osman Riazpp. 261-266Macrophage-Stimulating Protein Enhances Osteoblastic Differentiation via the Recepteur d'Origine Nantais Receptor and Extracellular Signal Regulated Kinase Signaling PathwayJeong-Tae Koh, 이미남, 정병철, Sin-Hye Ohpp. 267-279Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea이영균, 유준일, Yong-Chan Ha, Se Hwa Kim, 안승희, Hyoung Seok Jung, 노재휘, 김태영, 김하영, 장선미, 박상민, So Young Parkpp. 281-290
원문 보기